Data from a phase 1b/2a trial have raised doubts about whether Wave Life Sciences’ Huntington’s disease drug can compete with Roche and Ionis’ rival candidate. The results wiped 50% off Wave’s share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results